What is the Astellas Patient Assistance Program a?
The Astellas Patient Assistance Program a provides XTANDI ® (enzalutamide) at no cost to patients who meet the program eligibility requirements. XTANDI Support Solutions ®b can assess whether the patient meets the eligibility requirements.
What is Astellas Xtandi support solutions?
b XTANDI Support Solutions is a component of Astellas Pharma Support Solutions SM. c Other insured patients may be eligible for the program if they meet certain eligibility criteria.
Is the Xtandi Support Solutions Program void?
a The program is void where prohibited by law. b XTANDI Support Solutions is a component of Astellas Pharma Support Solutions SM. c Other insured patients may be eligible for the program if they meet certain eligibility criteria.
When can I contact Astellas Pharma support solutions?
We are available Monday–Friday, 9:00 AM–8:00 PM ET. Astellas Pharma Support Solutions is designed as a single point of contact to help patients understand their coverage and reimbursement options when they are prescribed an Astellas medication. We are here to answer questions about your insurance coverage or accessing your Astellas medication.
See more
What is the monthly cost of xtandi?
Xtandi Coupon & Prices - Cost $49 per month.
How do you get xtandi?
The Astellas Patient Assistance Program provides XTANDI at no cost to patients who meet the program eligibility requirements. All patients in this program who qualify receive their XTANDI prescription at no cost. Call 1-855-8XTANDI (1-855-898-2634) to see if you qualify.
Who is the manufacturer of xtandi?
About the Pfizer/Astellas Collaboration The companies jointly commercialize XTANDI in the United States and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United States.
What drug company makes myrbetriq?
Myrbetriq® is a registered trademark of Astellas Pharma Inc.
How long do people stay on Xtandi?
Median treatment duration was 40.2 months in the Xtandi group, just about 14 months on placebo and nearly 24 months in a group that had crossed over from placebo to Xtandi. About 34.5%, or 397 patients, remained on the treatment at the May 28 cutoff point with a median follow-up of nearly 45 months.
Does Medicare cover the drug Xtandi?
Do Medicare prescription drug plans cover Xtandi? Yes. 100% of Medicare prescription drug plans cover this drug.
Does Pfizer own Astellas?
In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE:PFE), and Astellas (TSE: 4503) entered into a global agreement to jointly develop and commercialize enzalutamide.
What happens when you stop taking Xtandi?
If your doctor thinks Xtandi has stopped working they will advise you to stop taking it. In about 50 percent of the men whose PSA level starts to rise again while on antiandrogen therapy, stopping treatment will lead to antiandrogen withdrawal syndrome or antiandrogen withdrawal response (AAWR).
Is there a generic form of Xtandi?
Enzalutamide is the generic name for the trade name drug Xtandi®.
How much does Myrbetriq cost at Walmart?
$506.50Average 12 Month Prices for MyrbetriqPharmacyMyrbetriq Retail PriceMyrbetriq SingleCare PriceWalmart$506.50$413.48Walgreens$538.83$436.24Kroger Pharmacy$512.26$411.91Albertsons Pharmacy$454.95$400.572 more rows
What is the new drug for incontinence?
Mirabegron (Myrbetriq) Mirabegron is a medication approved to treat certain types of urinary incontinence. It relaxes the bladder muscle and can increase how much urine the bladder can hold. It might also increase the amount you're able to urinate at one time.
Is Myrbetriq the same as Flomax?
Myrbetriq and Flomax belong to different drug classes. Myrbetriq is a beta-3 adrenergic agonist and Flomax is an alpha-blocker. Side effects of Myrbetriq and Flomax that are similar include sore throat, diarrhea, headache, dizziness, blurred vision, or nausea.
Is XTANDI a form of chemo?
XTANDI is an androgen receptor inhibitor; it is not a chemotherapy. Androgens are a group of hormones that includes testosterone. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.
Is XTANDI oral chemo?
Xtandi is not a chemotherapy drug despite being used to treat cancer. Xtandi is a type of hormone therapy that works to prevent prostate cancer cells from growing and spreading by blocking the action of a group of hormones called androgens.
Does XTANDI cause memory loss?
Other side effects include: lower respiratory tract infection, pneumonia, pulmonary infection, altered mental status, amnesia, bronchitis, cognitive dysfunction, falling, hypertension, hypoesthesia, and memory impairment.
What happens when you stop taking XTANDI?
If your doctor thinks Xtandi has stopped working they will advise you to stop taking it. In about 50 percent of the men whose PSA level starts to rise again while on antiandrogen therapy, stopping treatment will lead to antiandrogen withdrawal syndrome or antiandrogen withdrawal response (AAWR).
Can you get Xtandi prescriptions shipped to your home?
Your XTANDI prescription will then be shipped directly to your home.
Does Astellas provide Xtandi?
The Astellas Patient Assistance Program a provides XTANDI ® (enzalutamide) at no cost to patients who meet the program eligibility requirements .
How to contact Xtandi?
Call XTANDI Support Solutions® at 1-855-8XTANDI ( 1-855-898-2634 ) to speak with a dedicated access specialist who can help you find out what options exist for eligible patients to pay for XTANDI.
Does Astellas provide Xtandi?
The Astellas Patient Assistance Program provides XTANDI at no cost to patients who meet the program e ligibility requirements. ‡ All patients in this program who qualify receive their XTANDI prescription at no cost. Call 1-855-8XTANDI ( 1-855-898-2634) to see if you qualify.
What is Astellas Pharma Support Solutions?
Astellas Pharma Support Solutions is designed as a single point of contact to help patients understand their coverage and reimbursement options when they are prescribed an Astellas medication . We are here to answer questions about your insurance coverage or accessing your Astellas medication. Patients can find information online at http://www.astellaspharmasupportsolutions.com/patient/index.aspx. To speak with a dedicated access specialist, please call us at 1-800-477-6472. We are available Monday–Friday, 9:00 AM–8:00 PM ET.
How to contact Astellas Pharma?
To speak with a dedicated access specialist, please call us at 1-800-477-6472. We are available Monday–Friday, 9:00 AM–8:00 PM ET.
What are the lab abnormalities in Xtandi?
Lab Abnormalities: Lab abnormalities that occurred in ≥ 5% of patients, and more frequently ( > 2%) in the XTANDI arm compared to placebo in the pooled, randomized, placebo-controlled studies are neutrophil count decreased, white blood cell decreased, hyperglycemia, hypermagnesemia, hyponatremia, and hypercalcemia.
What are the most common ARs in Xtandi?
In the data from the four randomized placebo-controlled trials, the most common ARs ( ≥ 10%) that occurred more frequently ( ≥ 2% over placebo) in XTANDI-treated patients were asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, and hypertension. In the bicalutamide-controlled study, the most common ARs ( ≥ 10%) reported in XTANDI-treated patients were asthenia/fatigue, back pain, musculoskeletal pain, hot flush, hypertension, nausea, constipation, diarrhea, upper respiratory tract infection, and weight loss.
Does Xtandi cause seizures?
In a study of patients with predisposing factors for seizure, 2.2% of XTANDI-treated patients experienced a seizure. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Patients in the study had one or more of the following predisposing factors: use of medications that may lower the seizure threshold, history of traumatic brain or head injury, history of cerebrovascular accident or transient ischemic attack, and Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection. Advise patients of the risk of developing a seizure while taking XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during treatment.
Does Xtandi affect other drugs?
Effect of XTANDI on Other Drugs Avoid CYP3A4, CYP2C9, and CYP2C19 substrates with a narrow therapeutic index , as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.
Is Xtandi safe for women?
Embryo-Fetal Toxicity The safety and efficacy of XTANDI have not been established in females. XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment with XTANDI and for 3 months after the last dose of XTANDI.
Can Xtandi be taken with other drugs?
Effect of Other Drugs on XTANDI Avoid strong CYP2C8 inhibitors, as they can increase the plasma exposure to XTANDI. If co-administration is necessary, reduce the dose of XTANDI.
Did Amgen donate to Onyx?
The government alleged that Onyx was the sole donor to this travel fund and that Amgen, after integrating Onyx into its operations in 2015, continued to donate to the fund. The foundation also operated a second fund that covered copays for multiple myeloma drugs, including Kyprolis.
Does Astellas sell Xtandi?
Astellas : Astellas sells Xtandi, an androgen receptor inhibitor (ARI) used to treat certain prostate cancer; none of the other major drugs to treat the condition is an ARI. The government alleged that, in May 2013, Astellas asked two foundations about the creation of copay assistance funds to cover the copays for Medicare patients taking ARIs, but not for other types of prostate cancer drugs. In July 2013, both foundations opened ARI-only copay funds; Astellas was the sole donor to both funds. The government alleged that Astellas knew that Xtandi would likely account for the vast majority of utilization from each fund, and, in fact, Medicare patients taking Xtandi received nearly all of the copay assistance from the two ARI funds. The government further alleged that, during the time that the ARI funds were open, Astellas promoted the existence of the ARI funds as an advantage for Xtandi over competing drugs in an effort to persuade medical providers to prescribe Xtandi. Astellas has agreed to pay $100 million to resolve the government’s allegations.
Did Astellas pay $100 million for Xtandi?
The government further alleged that, during the time that the ARI funds were open, Astellas promoted the existence of the ARI funds as an advantage for Xtandi over competing drugs in an effort to persuade medical providers to prescribe Xtandi. Astellas has agreed to pay $100 million to resolve the government’s allegations.
Is Astellas an ARI only fund?
In July 2013, both foundations opened ARI-only copay funds; Astellas was the sole donor to both funds. The government alleged that Astellas knew that Xtandi would likely account for the vast majority of utilization from each fund, and, in fact, Medicare patients taking Xtandi received nearly all of the copay assistance from the two ARI funds.
Does Amgen sell Sensipar?
Amgen: Amgen sells the secondary hyperparathyroidism drug Sensipar and the multiple myeloma drug Kyprolis. Amgen acquired Kyprolis as part of its acquisition of Onyx Pharmaceuticals Inc. in 2013. With respect to Sensipar, the government alleged that, in late 2011, Amgen stopped donating to a foundation that provided financial support to patients taking any of several secondary hyperparathyroidism drugs and approached a new foundation about creating a “Secondary Hyperparathyroidism” fund that would support only Sensipar patients. Amgen allegedly worked with the new foundation to determine the fund’s coverage parameters and, in November 2011, the foundation launched a “Secondary Hyperparathyroidism” fund with Amgen as its sole donor. Until June 2014, the fund covered only Sensipar. Amgen allegedly made payments to the fund even though the cost of these payments exceeded the cost to Amgen of providing free Sensipar to financially needy patients. However, by enabling the fund to cover the copays of Medicare beneficiaries, Amgen caused claims to be submitted to Medicare and generated revenue for itself.